MY179833A - Chromenone derivatives with anti-tumour activity - Google Patents

Chromenone derivatives with anti-tumour activity

Info

Publication number
MY179833A
MY179833A MYPI2012001831A MYPI2012001831A MY179833A MY 179833 A MY179833 A MY 179833A MY PI2012001831 A MYPI2012001831 A MY PI2012001831A MY PI2012001831 A MYPI2012001831 A MY PI2012001831A MY 179833 A MY179833 A MY 179833A
Authority
MY
Malaysia
Prior art keywords
chromenone derivatives
tumour activity
chromenone
derivatives
medicament
Prior art date
Application number
MYPI2012001831A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Sebastien Louis Degorce
Der Brempt Christine Marie Paul Lambert-Van
Remy Robert Morgentin
Patrick Ple
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MY179833A publication Critical patent/MY179833A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MYPI2012001831A 2009-10-27 2010-10-25 Chromenone derivatives with anti-tumour activity MY179833A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09306017 2009-10-27

Publications (1)

Publication Number Publication Date
MY179833A true MY179833A (en) 2020-11-17

Family

ID=43085922

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2012001831A MY179833A (en) 2009-10-27 2010-10-25 Chromenone derivatives with anti-tumour activity

Country Status (41)

Country Link
US (5) US8399460B2 (enExample)
EP (1) EP2493870B1 (enExample)
JP (2) JP5657010B2 (enExample)
KR (1) KR101738195B1 (enExample)
CN (2) CN104447657B (enExample)
AR (1) AR078786A1 (enExample)
AU (1) AU2010311107B9 (enExample)
BR (1) BR112012010124B8 (enExample)
CA (1) CA2776994C (enExample)
CL (1) CL2012001056A1 (enExample)
CO (1) CO6541528A2 (enExample)
CR (1) CR20120217A (enExample)
CU (1) CU20120069A7 (enExample)
CY (1) CY1116143T1 (enExample)
DK (1) DK2493870T3 (enExample)
DO (1) DOP2012000124A (enExample)
EA (1) EA020523B9 (enExample)
EC (1) ECSP12011838A (enExample)
ES (1) ES2530943T3 (enExample)
GT (1) GT201200126A (enExample)
HN (1) HN2012000889A (enExample)
HR (1) HRP20150146T1 (enExample)
IL (1) IL219191A0 (enExample)
IN (1) IN2012DN03328A (enExample)
ME (1) ME02050B (enExample)
MX (1) MX2012005027A (enExample)
MY (1) MY179833A (enExample)
NI (1) NI201200081A (enExample)
NZ (1) NZ599457A (enExample)
PE (1) PE20130149A1 (enExample)
PH (1) PH12012500804A1 (enExample)
PL (1) PL2493870T3 (enExample)
PT (1) PT2493870E (enExample)
RS (1) RS53813B1 (enExample)
SA (1) SA110310808B1 (enExample)
SI (1) SI2493870T1 (enExample)
SM (1) SMT201500036B (enExample)
TW (1) TWI483939B (enExample)
UA (1) UA107474C2 (enExample)
UY (1) UY32978A (enExample)
WO (1) WO2011051704A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Pi3キナーゼの阻害薬
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
US8530470B2 (en) * 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
US9156831B2 (en) 2013-01-23 2015-10-13 Astrazeneca Ab Chemical compounds
CA2900136C (en) * 2013-03-04 2021-05-04 Astrazeneca Ab Combination treatment
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CA2952025A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CA2952044C (en) 2014-06-13 2019-01-29 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
MX2016016538A (es) 2014-06-13 2017-05-01 Gilead Sciences Inc Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa.
MX2016016516A (es) 2014-06-13 2017-05-01 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-cinasa.
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
KR101766731B1 (ko) 2015-06-23 2017-08-10 충남대학교산학협력단 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물
BR112018007068B1 (pt) * 2015-10-09 2024-01-02 Janssen Pharmaceutica N.V. Derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta, seu uso e composição farmacêutica que os compreende
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AR121719A1 (es) * 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
KR20210141214A (ko) * 2020-05-15 2021-11-23 제이투에이치바이오텍 (주) 3원환 화합물 및 이의 의약 용도
CN117615763A (zh) * 2021-02-01 2024-02-27 健道生物医药有限公司 磷酸肌醇3激酶β抑制剂及其组合物和制备方法
MX2023013082A (es) * 2021-05-03 2024-01-08 Petra Pharma Corp Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades.
CA3217937A1 (en) 2021-05-03 2022-11-10 Erin Danielle ANDERSON Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
CN117597343A (zh) * 2021-05-03 2024-02-23 佩特拉制药公司 用于治疗疾病的磷酸肌醇3-激酶(pi3k)的变构色烯酮抑制剂
MX2023013987A (es) * 2021-05-27 2024-02-12 Petra Pharma Corp Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer.
CN117769546A (zh) * 2021-05-27 2024-03-26 佩特拉制药公司 用于治疗疾病的磷酸肌醇3-激酶(pi3k)的变构色烯酮抑制剂
CN118043044A (zh) * 2021-09-30 2024-05-14 佩特拉制药公司 用于治疗疾病的磷酸肌醇3-激酶(pi3k)的变构色烯酮抑制剂
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
EP4412606A4 (en) * 2021-10-07 2025-09-24 Relay Therapeutics Inc PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
EP4444714A4 (en) * 2021-12-08 2025-10-29 Nanjing Zenshine Pharmaceuticals Co Ltd CONDENSED HETEROCYCLIC COMPOUNDS USED AS PI3KALPHA INHIBITORS
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
US20260130925A1 (en) * 2022-10-14 2026-05-14 Genesis Molecular Ai, Inc. Methods for treating cancer
CN119431297A (zh) * 2023-08-02 2025-02-14 郑州同源康医药有限公司 稠环类化合物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027A (en) * 1849-01-09 Rotary blacksmith s twyer
EP0459983A1 (en) 1988-12-21 1991-12-11 PHARMACIA & UPJOHN COMPANY Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
ATE158288T1 (de) 1990-06-20 1997-10-15 Upjohn Co Antiatherosklerotische und antithrombotische 1- benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on- derivate
DE4318756A1 (de) 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
ATE363471T1 (de) 2000-01-24 2007-06-15 Astrazeneca Ab Durch einen morpholinrest substituierte therapeutische verbindungen
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
EP1537102A4 (en) 2002-08-16 2010-12-08 Astrazeneca Ab INHIBITORS OF PHOSPHOINOSITIDE-3-KINASE BETA
AR054438A1 (es) * 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
AU2006303037A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
SI2004654T1 (sl) * 2006-04-04 2013-11-29 The Regents Of The University Of California Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
EP2112145A1 (en) 2008-04-24 2009-10-28 AxoGlia Therapeutics S.A. Chromenone derivatives useful for the treatment of neurodegenerative diseases
WO2010134082A1 (en) 2009-05-21 2010-11-25 Proteologics Ltd Chromenone derivatives for treatment of cancer
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives

Also Published As

Publication number Publication date
ECSP12011838A (es) 2012-06-29
CN102712615B (zh) 2014-12-17
CN104447657A (zh) 2015-03-25
NZ599457A (en) 2014-04-30
PT2493870E (pt) 2015-02-18
JP5872016B2 (ja) 2016-03-01
EP2493870A1 (en) 2012-09-05
JP5657010B2 (ja) 2015-01-21
US8399460B2 (en) 2013-03-19
US8673906B2 (en) 2014-03-18
BR112012010124B1 (pt) 2021-02-17
SI2493870T1 (sl) 2015-03-31
RS53813B1 (sr) 2015-06-30
DOP2012000124A (es) 2012-07-15
KR20120098724A (ko) 2012-09-05
CA2776994A1 (en) 2011-05-05
CU20120069A7 (es) 2012-10-15
CO6541528A2 (es) 2012-10-16
US9718800B2 (en) 2017-08-01
CA2776994C (en) 2017-10-31
US20140194419A1 (en) 2014-07-10
SA110310808B1 (ar) 2013-11-24
EA020523B1 (ru) 2014-11-28
CN104447657B (zh) 2016-08-17
DK2493870T3 (en) 2015-02-23
US9029374B2 (en) 2015-05-12
NI201200081A (es) 2012-11-07
BR112012010124A2 (pt) 2016-06-07
IN2012DN03328A (enExample) 2015-10-23
TW201121960A (en) 2011-07-01
ES2530943T3 (es) 2015-03-09
HK1174027A1 (en) 2013-05-31
PL2493870T3 (pl) 2015-04-30
CL2012001056A1 (es) 2012-10-05
ME02050B (me) 2015-05-20
AU2010311107B2 (en) 2014-03-27
UA107474C2 (uk) 2015-01-12
MX2012005027A (es) 2012-09-07
AU2010311107B9 (en) 2014-06-19
JP2015078202A (ja) 2015-04-23
CN102712615A (zh) 2012-10-03
WO2011051704A1 (en) 2011-05-05
CY1116143T1 (el) 2017-02-08
EP2493870B1 (en) 2014-12-17
PH12012500804A1 (en) 2022-10-03
US20160060240A1 (en) 2016-03-03
AR078786A1 (es) 2011-11-30
US20160272607A1 (en) 2016-09-22
GT201200126A (es) 2014-03-03
KR101738195B1 (ko) 2017-05-19
EA020523B9 (ru) 2015-01-30
US20110098271A1 (en) 2011-04-28
PE20130149A1 (es) 2013-03-10
TWI483939B (zh) 2015-05-11
UY32978A (es) 2011-05-31
HK1206335A1 (zh) 2016-01-08
HN2012000889A (es) 2015-08-03
AU2010311107A1 (en) 2012-05-03
HRP20150146T1 (hr) 2015-05-22
SMT201500036B (it) 2015-05-05
US20130158026A1 (en) 2013-06-20
CR20120217A (es) 2012-06-28
EA201200618A1 (ru) 2012-12-28
JP2013508449A (ja) 2013-03-07
IL219191A0 (en) 2012-06-28
BR112012010124B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
PH12012500804A1 (en) Chromenone derivatives with anti-tumour activity
MX340300B (es) Compuestos de cromenona como inhibidores de pi 3-quinasa para el tratamiento del cancer.
TW200745040A (en) Quinoline derivatives
MD4590B1 (ro) Derivaţi macrociclici pentru tratamentul bolilor proliferative
PH12014501542B1 (en) Substituted pyrrolidine -2- carboxamides
PH12015502615B1 (en) Chemical compounds
MY148948A (en) Catecholamine derivatives and prodrugs thereof
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MY162535A (en) Inhibitors of arginase and their therapeutic applications
IN2014DN03206A (enExample)
MY158193A (en) Morpholino pyrimidines and their use in therapy
MY168159A (en) Bicyclic heterocycle compounds and their uses in therapy
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
MY165624A (en) N-acylsulfonamide apoptosis promoters
GB201209587D0 (en) Therapeutic compounds
MX2012008328A (es) Derivados de pirazina.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
TW201613864A (en) Novel compounds
MX340574B (es) Imidazo pirazinas.
MX341577B (es) Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero.
TW200745085A (en) Quinoline derivatives
PH12015500399A1 (en) Azaindolines
MX2014001862A (es) 5-cicloalquil-o 5-heterociclil-nicotinamidas.
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
BR112013024722A2 (pt) compostos de complexo de pirimidina-2-ol-1-óxido de ferro(iii) ou seus sais farmaceuticamente aceitáveis, medicamento e composição